How does Worldwide ensure specialized, experienced teams execute our rare disease studies? How does patient education play into our study delivery? Watch EBD Group’s interview with Global Vice President, Therapeutic Strategy, Rare Disease and Oncology, Derek Ansel, to find out more about how we approach rare disease studies.
Authors:
Derek Ansel, MS, LCGC
Global Vice President, Therapeutic Strategy, Rare Disease and Oncology
